 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, today announced ZYNLONTATM loncastuximab tesirine-lpyl has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines NCCN Guidelines in oncology for B-cell Lymphomas. Specifically, the NCCN Guidelines now include ZYNLONTA as 